Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
Status:
Completed
Trial end date:
2020-05-04
Target enrollment:
Participant gender:
Summary
The overall aim of this study is to assess the effects of a new treatment called Secukinumab
in adults suffering from moderate to severe atopic dermatitis. Furthermore, the study shall
support the extension of the approval for Secukinumab from psoriasis to atopic dermatitis.
The effectiveness of Secukinumab is determined on the reduction of the eczema score EASI 50
(Eczema Area and Severity Index, a tool to measure the severity of atopic dermatitis) at week
4.